Obesity market news — September 8, 2026
The most consequential number this week came from a paediatric dataset, not from a company. A study published on September 4 by researchers at NYU Langone Health followed more than 3.5 million US children aged eight to eleven who had obesity but not diabetes. Of those, 20,282 received a GLP-1 receptor agonist. The treated share rose from 0.03 percent in 2019 to 9.3 percent by June 2026, roughly a 310-fold increase, and the medicine most often prescribed was Novo Nordisk's Wegovy. Ninety-four percent of the treated children had severe obesity and about sixty-five percent had at least one related condition such as high cholesterol, hypertension or sleep apnoea. The regulatory position is what makes this material: these medicines are not approved in the United States for children under twelve, while clinical guidelines permit use from age eight in selected cases. What is growing is therefore off-label volume in a population for which long-term safety data does not yet exist. The reading cuts both ways. A paediatric label would be a genuine expansion, and the prescribing pattern shows the demand is already there. But volume that arrives ahead of a label is also the kind that regulators, payers and journalists revisit later, and the lead investigator's own comment was that long-term safety monitoring is needed.
The constraint on this market has not been supply for some time; it is who pays. Marsh's 2026 National Survey of Employer-Sponsored Health Plans, covering more than 1,800 US employers, puts the expected rise in total health benefit cost per employee at 8.2 percent for 2027, the largest increase since 2003. GLP-1 medicines sit at the top of the list of cost drivers, and rising GLP-1 utilisation accounts for a full percentage point of that growth on its own. The Segal Health Plan Cost Trend Survey arrives at the same place by a different route, describing the fastest growth in employer plan costs in fifteen years for 2027. The part worth watching is not the headline percentage but the response to it: some employers, needing immediate relief, have chosen to drop weight-management coverage for next year. That is the same retreat this publication set out in numbers on August 25, now expressed as a budgeting decision for a specific plan year. Prescription growth and coverage growth are diverging, and the gap between them is where the revenue question actually sits. A prescription that no plan pays for is not revenue.
Three dated commitments recorded in the August 31 edition are still open, and the quarter now has twenty-two days left. Structure Therapeutics has guided the start of the Phase 3 programme of aleniglipron, its oral small molecule GLP-1, to the third quarter of 2026. Viking Therapeutics has guided topline data from VANQUISH-2, the Phase 3 trial in participants with type 2 diabetes, to the third quarter of 2026. Zealand Pharma and Roche, in their half-year report of August 13, guided the start of registrational Phase 3 trials of petrelintide monotherapy to the second half of 2026, which leaves them more room than the other two. As of September 8 none of the three had been announced. We are not forecasting slippage, and a company that delivers in the last week of a quarter has kept its word. We are recording that the window is narrowing, because the alternative is to notice only afterwards, when the explanation has already been written by someone else. The one commitment in this group that has been met belongs to Ascletis, which dosed the first participant in its global Phase 3 programme on August 30.
NYU Langone Health: A study of more than 3.5 million US children aged eight to eleven with obesity and without diabetes found that 20,282 received a GLP-1 receptor agonist, with the treated share rising from 0.03 percent in 2019 to 9.3 percent by June 2026. Wegovy was the medicine most often prescribed. Ninety-four percent of treated children had severe obesity; about sixty-five percent had at least one associated condition. GLP-1 medicines are not approved in the United States below age twelve, though guidelines allow use from age eight in selected cases.
Nature / UC Berkeley / US National Institutes of Health: A paper published in Nature on September 2 reported that semaglutide extended the lifespan of older, healthy mice. Treated animals reached a median lifespan of 834 days against 742 days in controls, about twelve percent longer, and outperformed a calorie-restricted comparison group on several measures including a spatial memory task. This is a mouse result and no human relevance has been established. It is recorded here because it will shape the public conversation around these medicines well before any clinical work follows, and that conversation reaches payers and prescribers too.
Marsh, Segal: Marsh's 2026 National Survey of Employer-Sponsored Health Plans, covering more than 1,800 US employers, expects total health benefit cost per employee to rise 8.2 percent in 2027, the largest increase since 2003. GLP-1 medicines lead the list of cost drivers and rising GLP-1 utilisation accounts for one full percentage point of that growth. The Segal Health Plan Cost Trend Survey describes the fastest growth in employer plan costs in fifteen years for the same year. Some employers have responded by dropping weight-management coverage for 2027.
Structure Therapeutics (GPCR), Viking Therapeutics (VKTX), Zealand Pharma (ZEAL): Follow-up on the three guided windows recorded on August 31. Structure Therapeutics: Phase 3 start for aleniglipron guided to the third quarter of 2026, not yet announced. Viking Therapeutics: VANQUISH-2 topline guided to the third quarter of 2026, not yet announced. Zealand Pharma and Roche: registrational Phase 3 start for petrelintide monotherapy guided to the second half of 2026, not yet announced, with more room in the calendar than the other two. Twenty-two days remain in the quarter. Status unchanged since the last edition.
US metabolic and bariatric surgery: A correction on dating, because the figure circulated widely again this week. Between 2022 and 2024, GLP-1 use for weight management among US adults with obesity, overweight or diabetes rose 140.4 percent while metabolic bariatric surgery rates fell 34.1 percent; a little over 177,000 procedures took place in 2024 against a peak above 230,000 in 2022, a 23 percent decline. Those numbers describe 2022 to 2024 and were published in May 2026. Nothing new was measured this week. The trend is real; the freshness implied by this week's coverage is not.
Tekton Research: Two Tekton Research sites, in San Antonio and Edmond, randomised 60 participants into a Phase 2 obesity trial against a combined target of 20, three times the goal. This is a site-level operational item rather than a clinical result, and it is recorded because trial site capacity to identify and screen suitable obesity patients is a real constraint on how fast dose-finding studies read out. Which sponsor's molecule was studied is not identified in the announcement.
Amgen (AMGN): No dated change at Amgen in this window. For context, MariTide, a long-acting peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism, is in nine global Phase 3 studies across obesity, obstructive sleep apnoea, cardiovascular disease and heart failure. The Phase 2 results reported roughly 20 percent average weight loss without a plateau at 52 weeks in participants without type 2 diabetes. The primary readout for MARITIME-1 is guided to early 2027, which places Amgen outside the current quarter's watchlist.
Eli Lilly (LLY), Novo Nordisk (NVO): Neither market leader produced a dated corporate change between September 1 and September 8. Both are nevertheless present in this edition through other parties' data: Wegovy was the medicine most often prescribed in the paediatric study, and semaglutide was the molecule in the Nature mouse work. That is worth separating clearly. Neither item is company news, neither was generated by the companies, and neither carries a regulatory consequence today. Disclosure: the author holds shares in Eli Lilly and Novo Nordisk. The full statement is on the About page.